A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.
In spite of the many drugs available to treat breast cancer, resistance continues to be a problem.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.
The initiative aims to raise 25,000 euros to fund the first year of a PhD student at IRB Barcelona.
The campaign is part of "Giving Tuesday", a day devoted to charitable donations, which this year falls on Tuesday 29 November.
He is awarded this prize for his work on colon cancer
This prestigious prize is given in recognition of molecular biology research performed by scientists working in Spain
The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
Scientists from the US, Canada and Spain, among them Joan Guinovart from IRB Barcelona, are poised to perform joint research with the aim to find a treatment for Lafora disease, the most severe type of epilepsy in humans.
The National Health Institutes has awarded the consortium $8.5 over five years.
The US organisation Chelsea’s Hope, a charity formed by families affected by this disease, has promoted this international collaboration.
IRB Barcelona fosters entrepreneurship among its young scientists. Two postdoctoral fellows tell in vivo about their experience of learning how to deal with markets, patents and venture capitalists.
The Bilbao Exhibition Center (BEC) in Barakaldo (Vizcaya) is the venue of BioSpain 2016, the eighth of these biennial biotech gatherings, the most important event in this sector in Europe and permanently held in Spain, and fifth-ranked event worldwide for the number of partnering meetings held.
Report in La Vanguardia on how researchers go about discovering new compounds with therapeutic potential from the marine environment. The article makes reference a study performed by former IRB Barcelona researcher Mercedes Álvarez on baringolin, a molecule with antibiotic activity obtained from a marine microorganism off the coast of Alicante. Compounds of marine origin with biomedical interest arise due to the...